Payment overview · 2025
General Payments
$1,187.83
62 reported records · 10 companies
Healthcare provider profile · identity verified
Anna Chan, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · FLUSHING, NY · NPI 1477851103
Verified facts
What the public records show
CMS Open Payments records show Anna Chan, M.D. received $1,187.83 in general payments during 2025 across 62 reported records.
Gilead Sciences, Inc. accounted for 32.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ibsrela, Jardiance, Ozempic, Prolia, Rybelsus, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 172 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Prolia by this doctor in 2024.
Ardelyx, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IBSRELA as an associated drug or biological on 59980 records involving 18215 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Ibsrela by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Nexium by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 248 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Synjardy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Vemlidy by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $387.24 | 32.6% | 18 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $229.13 | 19.3% | 12 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $189.26 | 15.9% | 13 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $125.58 | 10.6% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $66.72 | 5.6% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $65.43 | 5.5% | 4 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $51.46 | 4.3% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $40.69 | 3.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.97 | 1.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.35 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,187.83 | 62 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $229.13 | 12 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $189.26 | 13 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $125.58 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $66.72 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $66.72 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $65.43 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $40.69 | 2 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $28.95 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $22.51 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $14.44 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| IBSRELA ibsrela |
2025 | Ibsrela | 2024 | 21 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 248 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 102 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
172 | 25 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
140 | 31 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Ardelyx, Inc. Exact reporting entity; no affiliate inference |
2025 | IBSRELA open payments reported associated product |
CMS Open Payments — General Payments 59980 supporting records · 18215 recipient NPIs · example record 1247828901 |
Ibsrela · 2024 Exact normalized brand match · 1 Part D row |
21 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
101 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
248 | 37 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
112 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
102 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Vascepa | Icosapent Ethyl | 965 | 134 |
| Atorvastatin Calcium | Atorvastatin Calcium | 935 | 130 |
| Amlodipine Besylate | Amlodipine Besylate | 626 | 80 |
| Losartan Potassium | Losartan Potassium | 547 | 68 |
| Diclofenac Epolamine | Diclofenac Epolamine | 545 | 77 |
| Alendronate Sodium | Alendronate Sodium | 538 | 70 |
| Clobetasol Propionate | Clobetasol Propionate | 516 | 72 |
| Tacrolimus | Tacrolimus | 498 | 64 |
| Mesalamine | Mesalamine | 475 | 57 |
| Mometasone Furoate | Mometasone Furoate | 453 | 70 |
| Metformin Hcl | Metformin Hcl | 407 | 63 |
| Ammonium Lactate | Ammonium Lactate | 347 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 325 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 316 | 85 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 305 | 55 |
| Omeprazole | Omeprazole | 304 | 55 |
| Diclofenac Sodium | Diclofenac Sodium | 292 | 71 |
| Simvastatin | Simvastatin | 291 | 33 |
| Ketoconazole | Ketoconazole | 290 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 283 | 37 |
| Meclizine Hcl | Meclizine Hcl | 250 | 44 |
| Jardiance | Empagliflozin | 248 | 37 |
| Restasis | Cyclosporine | 226 | 46 |
| Trazodone Hcl | Trazodone Hcl | 224 | 34 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 217 | 31 |
| Hydrocortisone | Hydrocortisone | 207 | 30 |
| Allopurinol | Allopurinol | 202 | 22 |
| Bepotastine Besilate | Bepotastine Besilate | 196 | 34 |
| Famotidine | Famotidine | 192 | 39 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 192 | 39 |
| Halobetasol Propionate | Halobetasol Propionate | 191 | 35 |
| Azelastine Hcl | Azelastine Hcl | 181 | 41 |
| Creon | Lipase/Protease/Amylase | 172 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 171 | 27 |
| Metformin Er Gastric | Metformin Hcl | 160 | 19 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 157 | 23 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 157 | 28 |
| Lubiprostone | Lubiprostone | 147 | 19 |
| Raloxifene Hcl | Raloxifene Hcl | 147 | 21 |
| Donepezil Hcl | Donepezil Hcl | 146 | 23 |
| Linzess | Linaclotide | 140 | 31 |
| Finasteride | Finasteride | 139 | 15 |
| Gabapentin | Gabapentin | 137 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 131 | 24 |
| Cyclosporine | Cyclosporine | 127 | 37 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 127 | 42 |
| Atenolol | Atenolol | 125 | 14 |
| Levothyroxine Sodium | Levothyroxine Sodium | 116 | 18 |
| Vemlidy | Tenofovir Alafenamide | 112 | 13 |
| Icosapent Ethyl | Icosapent Ethyl | 110 | 57 |
| Diflorasone Diacetate | Diflorasone Diacetate | 106 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 104 | 17 |
| Rybelsus | Semaglutide | 102 | 14 |
| Farxiga | Dapagliflozin Propanediol | 101 | 14 |
| Clobetasol Emollient | Clobetasol Propionate/Emoll | 99 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 94 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 89 | 14 |
| Oxiconazole Nitrate | Oxiconazole Nitrate | 88 | 17 |
| Aripiprazole | Aripiprazole | 87 | 13 |
| True Comfort Pro Alcohol Pads | Alcohol Antiseptic Pads | 83 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 79 | 11 |
| Eliquis | Apixaban | 77 | 11 |
| Glipizide Er | Glipizide | 76 | suppressed |
| Lisinopril | Lisinopril | 76 | 15 |
| Januvia | Sitagliptin Phosphate | 74 | suppressed |
| Nitroglycerin | Nitroglycerin | 74 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 66 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 62 | 12 |
| Nifedipine Er | Nifedipine | 62 | suppressed |
| Mupirocin | Mupirocin Calcium | 61 | 23 |
| Lactulose | Lactulose | 60 | 33 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 59 | suppressed |
| Valsartan | Valsartan | 58 | suppressed |
| Fenofibrate | Fenofibrate | 57 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 56 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 56 | 15 |
| Colchicine | Colchicine | 55 | suppressed |
| Telmisartan | Telmisartan | 54 | suppressed |
| Furosemide | Furosemide | 52 | suppressed |
| Naproxen | Naproxen | 52 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 51 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 50 | suppressed |
| Folic Acid | Folic Acid | 50 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 50 | 14 |
| Ciclopirox | Ciclopirox Olamine | 48 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 47 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 46 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 46 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 45 | suppressed |
| Carvedilol | Carvedilol | 44 | suppressed |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 43 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 42 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 41 | 15 |
| Alcohol Pads | Alcohol Antiseptic Pads | 39 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Gemfibrozil | Gemfibrozil | 38 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 38 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 37 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 36 | suppressed |
| Mirtazapine | Mirtazapine | 35 | suppressed |
| Nexium | Esomeprazole Magnesium | 35 | suppressed |
| Acyclovir | Acyclovir | 34 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 34 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 34 | suppressed |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 33 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 33 | suppressed |
| Tavaborole | Tavaborole | 33 | 16 |
| Procto-Med Hc | Hydrocortisone | 31 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 29 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 28 | 14 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 28 | suppressed |
| Lansoprazole | Lansoprazole | 28 | suppressed |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Acarbose | Acarbose | 26 | suppressed |
| Irbesartan | Irbesartan | 25 | suppressed |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Latanoprost | Latanoprost | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | suppressed |
| Nateglinide | Nateglinide | 23 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 23 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 22 | 21 |
| Dexlansoprazole Dr | Dexlansoprazole | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Ibsrela | Tenapanor Hcl | 21 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 18 |
| Repaglinide | Repaglinide | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Loperamide | Loperamide Hcl | 19 | 17 |
| Methylprednisolone | Methylprednisolone | 19 | 15 |
| Prednisone | Prednisone | 19 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Meloxicam | Meloxicam | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 17 | suppressed |
| Azithromycin | Azithromycin | 17 | 14 |
| Celecoxib | Celecoxib | 17 | suppressed |
| Ciclopirox | Ciclopirox | 17 | suppressed |
| Entecavir | Entecavir | 17 | suppressed |
| Fluorometholone | Fluorometholone | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | 11 |
| Spironolactone | Spironolactone | 17 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 16 | suppressed |
| Fluocinonide | Fluocinonide | 16 | suppressed |
| Ozempic | Semaglutide | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 14 | suppressed |
| Hydroxyurea | Hydroxyurea | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Timolol Maleate | Timolol Maleate | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Proctozone-Hc | Hydrocortisone | 13 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Zafirlukast | Zafirlukast | 13 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 12 | suppressed |
| Ertaczo | Sertaconazole Nitrate | 12 | suppressed |
| Erythromycin | Erythromycin Base | 12 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Olopatadine Hcl | Olopatadine Hcl | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Pimecrolimus | Pimecrolimus | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,187.83 · 62 records | Gilead Sciences, Inc. | AIRSUPRA, Cologuard Collection Kit, EVENITY, IBSRELA, JARDIANCE, Ozempic, PROLIA, QULIPTA, Rybelsus, UBRELVY, VOWST, XIFAXAN, ZENPEP | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ibsrela play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error